It has been shown, however, that combination of anti-EGFR antibodies, namely cetuximab and nimotuzumab with radiotherapy reduces the number of CD133-positive tumor initiating cells (Diaz Miqueli et al., 2009). This evidence concerns the gene EGFR and neoplasm.